RT Journal Article
SR Electronic
T1 Are men dying more than women by COVID-19?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.06.20147629
DO 10.1101/2020.07.06.20147629
A1 Thaise Pinto de Melo
A1 Delvan Alves Silva
A1 Alexandre Naime Barbosa
YR 2020
UL http://medrxiv.org/content/early/2020/07/07/2020.07.06.20147629.abstract
AB We aimed to clarify if the infection and death rate by COVID-19 differ among gender in the top 50 countries with the highest death rates. Also, we investigated if secondary variables such as HDI, number of hospital beds, average age, temperature, percentage of elderly, smoker and obesity are contributing to the variability observed among countries. Meta-analyses and meta-regressions approaches were applied to official public data reported by the Word Health Organization and governments until May, 2020. A random effect model was used for the meta-analysis and heterogeneity was calculated by I2 statistic. There was not significative difference between men and women to be infected by COVID-19 (P = 0.42), though a significative difference was observed for death rate (P < 0.0001). High heterogeneity was observed among countries. For both infection and death rates this variability was mainly explained by the HDI (42.3% and 54.2%), average age (40.9% and 40.3%) and temperature (30.1% and 39.3%). Man are dying more than women around the word by COVID-19. Countries with highest HDI present less difference between sexes. These results reinforce that public politics promoting social isolation, health care and general well-being of the population are key factors in combating COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the national post-doctoral program of CAPES, Higher Education Improvement Coordination agency, Grant [number 88887.355147/2019-00].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not Applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is publicly available in the official bodies of the countries studied. https://globalhealth5050.org/covid19/ https://data.humdata.org/ https://data.oecd.org/healtheqt/hospital-beds.htm